查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1301042

雙特異性抗體市場規模、份額、趨勢分析報告：按適應症、按地區、細分市場趨勢，2023-2030 年

Bispecific Antibodies Market Size, Share & Trends Analysis Report By Indication (Cancer, Inflammatory & Autoimmune disorders), By Region (North America, Europe, Asia Pacific), And Segment Forecasts, 2023 - 2030
出版日期: | 出版商: Grand View Research | 英文 120 Pages | 商品交期: 2-10個工作天內

價格

雙特異性抗體市場增長和趨勢

根據 GrandView Research, Inc. 的最新報告，預計 2030 年將達到 1103 億美元。

癌症患病率不斷上升，例如乳腺癌、肺癌、前列腺癌和其他慢性疾病是市場增長的主要驅動力。 這些分子通過同時靶向癌細胞和免疫系統，提供了治療某些類型癌症的靶向方法。 此外，對個性化醫療的需求不斷增長以及向靶向治療的轉變也促進了市場的增長。

此外，製藥公司和生物技術公司之間的合作和夥伴關係在推進雙特異性抗體的研發方面發揮著重要作用。 這種聯合研究加速了新型雙特異性抗體的發現和臨床開發，進一步促進了市場增長。 例如，2022 年 1 月，安進和Generate Biomedicines 簽訂了一項研究合作協議，針對不同治療領域和模式的五個臨床靶點發現和開發蛋白質療法。 此外，2023年5月，美國 FDA 批准 EPKINLY (epcoritamab-bysp) 用於治療復發或難治性瀰漫性大 B 細胞淋巴瘤 (DLBCL)。

COVID-19 大流行對雙特異性抗體行業產生了雙重影響。 一方面，他強調了雙特異性抗體在對抗傳染病方面的重要性。 然而，疫情也帶來了供應鏈中斷的挑戰，導致雙特異性抗體的研發被推遲。 此外，經濟不確定性和預算限制可能會影響研究機構和生物技術公司，影響雙特異性抗體的開發優先事項和資源分配。

此外，進入新興國家的企業的各種發展以及產學界合作的增加正在極大地推動全球市場。 例如，2023 年 3 月，Thermo Fisher Scientific 與細胞治療公司 Arsenal Biosciences 合作，加速和支持自體 T 細胞療法的臨床生產。

雙特異性抗體市場報告亮點

  • 有跡象表明，由於全球範圍內癌症的高患病率，腫瘤學領域在 2022 年以 70.4% 的份額佔據市場主導地位。 此外，雙特異性抗體專門針對腫瘤細胞和腫瘤相關抗原，同時不傷害健康細胞。
  • 由於治療類風濕關節炎、牛皮癬、克羅恩病、多發性硬化症等的雙特異性抗體藥物的採用和開發增多，炎症和自身免疫性疾病領域將從2023 年到2030 年實現增長。預計複合年增長率將達到35.7 ％ 這些年來。
  • 憑藉高度發達的醫療基礎設施和有利的政府政策，北美已在全球市場上確立了穩固的地位，到 2022 年將佔據 89.5% 的市場份額。

內容

第1章調查方法及範圍

  • 信息獲取
  • 信息或數據分析
  • 市場範圍和細分定義
  • 市場模式
    • 按公司市場份額進行市場調查
    • 區域分析

第 2 章執行摘要

  • 市場概況
  • 片段快照
  • 競爭格局快照

第3章市場變量、趨勢和範圍

  • 市場體系展望
    • 母公司市場前景
    • 相關/補充市場前景
  • 市場動態
    • 市場驅動因素分析
    • 市場製約因素分析
  • 行業分析工具
    • 波特五力分析
    • PESTEL 分析
    • COVID-19 感染的影響分析
  • 管道分析

第 4 章：指標業務分析

  • 雙特異性抗體市場：適應症的變異分析
  • 癌症
  • 炎症和自身免疫性疾病
  • 其他

第 5 章區域業務分析

  • 2022 年和 2030 年按地區劃分的雙特異性抗體市場份額
  • 北美
    • 北美雙特異性抗體市場，2018-2030
    • 美國
    • 加拿大
  • 歐洲
    • 歐洲雙特異性抗體市場，2018-2030
    • 英國
    • 德國
  • 亞太地區
    • 亞太地區雙特異性抗體市場，2018-2030
    • 日本
    • 中國
  • 世界其他地區
    • 世界其他地區雙特異性抗體市場，2018-2030

第 6 章競爭格局

  • 公司分類
  • 戰略規劃
  • 2022 年公司市場份額分析
  • 公司簡介/列表
    • Amgen
    • Roche
    • Genentech
    • Akeso, Inc
    • Janssen
    • Taisho Pharmaceutical
    • Immunocore
Product Code: GVR-4-68040-088-4

Bispecific Antibodies Market Growth & Trends

The global bispecific antibodies market size is expected to reach USD 110.3 billion by 2030, expanding at a CAGR of 44.0% from 2023 to 2030, according to a new report by Grand View Research, Inc. The increasing prevalence of cancers such as breast cancer, lung cancer, prostate cancer, and other chronic diseases is a major driver for market growth. These molecules provide a targeted approach to treat specific types of cancer by simultaneously targeting cancer cells and the immune system. Additionally, the rising demand for personalized medicine and the shift toward targeted therapies have contributed to the market's growth.

Moreover, collaborations and partnerships between pharmaceutical companies and biotechnology firms have played a crucial role in advancing bispecific antibody research and development. These collaborations have accelerated the discovery and clinical development of novel bispecific antibodies, further propelling the market growth. For instance, in January 2022, Amgen and Generate Biomedicines established a research partnership agreement to discover and develop protein therapies for five clinical targets spanning different therapeutic areas and modalities. In addition to it, in May 2023, The U.S. FDA approved EPKINLY (epcoritamab-bysp) as the inaugural bispecific antibody to be authorized for the treatment of relapsed or refractory Diffuse Large B-Cell Lymphoma (DLBCL) in adult patients.

The COVID-19 pandemic has had a dual impact on the bispecific antibodies industry. On one hand, it has underscored the significance of bispecific antibodies in addressing infectious diseases. However, the pandemic has also introduced challenges in the form of supply chain disruptions, leading to delays in the research and development of bispecific antibodies. Furthermore, economic uncertainties and budget constraints have affected research institutions and biotech companies, potentially influencing their prioritization and allocation of resources towards bispecific antibody development.

Furthermore, various developments undertaken by participants, and increasing industry-academia collaborations have driven the global market to a significant extent. For instance, in March 2023, Thermo Fisher Scientific Inc collaborated with Arsenal Bioscience, a cell therapy company to facilitate and support the clinical manufacturing of Autologous T-Cell Therapies.

Bispecific Antibodies Market Report Highlights

  • By indication, the cancer segment dominated the market with a share of 70.4% in 2022, due high prevalence of cancer globally. Furthermore, bispecific antibodies specifically target tumor cells or tumor-associated antigens while sparing healthy cells
  • Inflammatory and autoimmune disorders segment is expected to grow at a significant CAGR of 35.7% during 2023-2030, owing to the increasing adoption and development of bispecific antibody drugs for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease, and multiple sclerosis among others.
  • North America established a strong regional position in the global market with an 89.5% share in 2022 due to its highly developed healthcare infrastructure and favorable government policies

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Information Procurement
  • 1.2. Information Or Data Analysis
  • 1.3. Market Scope & Segment Definition
  • 1.4. Market Model
    • 1.4.1. Market Study, By Company Market Share
    • 1.4.2. Regional Analysis

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Related/Ancillary Market Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
      • 3.2.1.1. Growing prevalence of chronic diseases
      • 3.2.1.2. Increasing investment in biologics research and development
    • 3.2.2. Market Restraint Analysis
      • 3.2.2.1. High development cost
  • 3.3. Industry Analysis Tools
    • 3.3.1. Porter's Five Forces Analysis
    • 3.3.2. PESTEL Analysis
    • 3.3.3. COVID-19 Impact Analysis
  • 3.4. Pipeline Analysis

Chapter 4. Indication Business Analysis

  • 4.1. Bispecific Antibodies Market: Indication Movement Analysis
  • 4.2. Cancer
    • 4.2.1. Cancer Market, 2018 - 2030 (USD Million)
  • 4.3. Inflammatory & Autoimmune Disorders
    • 4.3.1. Inflammatory & Autoimmune Disorders Market, 2018 - 2030 (USD Million)
  • 4.4. Others
    • 4.4.1. Others Market, 2018 - 2030 (USD Million)

Chapter 5. Regional Business Analysis

  • 5.1. Bispecific Antibodies Market Share By Region, 2022 & 2030
  • 5.2. North America
    • 5.2.1. North America Bispecific Antibodies Market, 2018 - 2030 (USD Million)
    • 5.2.2. The U.S.
      • 5.2.2.1. Key Country Dynamics
      • 5.2.2.2. Target Disease Prevalence
      • 5.2.2.3. Competitive Scenario
      • 5.2.2.4. Regulatory Framework
      • 5.2.2.5. U.S. Bispecific Antibodies Market, 2018 - 2030 (USD Million)
    • 5.2.3. Canada
      • 5.2.3.1. Key Country Dynamics
      • 5.2.3.2. Target Disease Prevalence
      • 5.2.3.3. Competitive Scenario
      • 5.2.3.4. Regulatory Framework
      • 5.2.3.5. Canada Bispecific Antibodies Market, 2018 - 2030 (USD Million)
  • 5.3. Europe
    • 5.3.1. Europe Bispecific Antibodies Market, 2018 - 2030 (USD Million)
    • 5.3.2. UK
      • 5.3.2.1. Key Country Dynamics
      • 5.3.2.2. Target Disease Prevalence
      • 5.3.2.3. Competitive Scenario
      • 5.3.2.4. Regulatory Framework
      • 5.3.2.5. UK Bispecific Antibodies Market, 2018 - 2030 (USD Million)
    • 5.3.3. Germany
      • 5.3.3.1. Key Country Dynamics
      • 5.3.3.2. Target Disease Prevalence
      • 5.3.3.3. Competitive Scenario
      • 5.3.3.4. Regulatory Framework
      • 5.3.3.5. Germany Bispecific Antibodies Market, 2018 - 2030 (USD Million)
  • 5.4. Asia Pacific
    • 5.4.1. Asia Pacific Bispecific Antibodies Market, 2018 - 2030 (USD Million)
    • 5.4.2. Japan
      • 5.4.2.1. Key Country Dynamics
      • 5.4.2.2. Target Disease Prevalence
      • 5.4.2.3. Competitive Scenario
      • 5.4.2.4. Regulatory Framework
      • 5.4.2.5. Japan Bispecific Antibodies Market, 2018 - 2030 (USD Million)
    • 5.4.3. China
      • 5.4.3.1. Key Country Dynamics
      • 5.4.3.2. Target Disease Prevalence
      • 5.4.3.3. Competitive Scenario
      • 5.4.3.4. Regulatory Framework
      • 5.4.3.5. China Bispecific Antibodies Market, 2018 - 2030 (USD Million)
  • 5.5. Rest of the world
    • 5.5.1. Rest of the world Bispecific Antibodies Market, 2018 - 2030 (USD Million)

Chapter 6. Competitive Landscape

  • 6.1. Company Categorization
  • 6.2. Strategy Mapping
  • 6.3. Company Market Share Analysis, 2022
  • 6.4. Company Profiles/Listing
    • 6.4.1. Amgen
      • 6.4.1.1. Overview
      • 6.4.1.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 6.4.1.3. Product Benchmarking
      • 6.4.1.4. Strategic Initiatives
    • 6.4.2. Roche
      • 6.4.2.1. Overview
      • 6.4.2.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 6.4.2.3. Product Benchmarking
      • 6.4.2.4. Strategic Initiatives
    • 6.4.3. Genentech
      • 6.4.3.1. Overview
      • 6.4.3.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 6.4.3.3. Product Benchmarking
      • 6.4.3.4. Strategic Initiatives
    • 6.4.4. Akeso, Inc
      • 6.4.4.1. Overview
      • 6.4.4.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 6.4.4.3. Product Benchmarking
      • 6.4.4.4. Strategic Initiatives
    • 6.4.5. Janssen
      • 6.4.5.1. Overview
      • 6.4.5.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 6.4.5.3. Product Benchmarking
      • 6.4.5.4. Strategic Initiatives
    • 6.4.6. Taisho Pharmaceutical
      • 6.4.6.1. Overview
      • 6.4.6.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 6.4.6.3. Product Benchmarking
      • 6.4.6.4. Strategic Initiatives
    • 6.4.7. Immunocore
      • 6.4.7.1. Overview
      • 6.4.7.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 6.4.7.3. Product Benchmarking
      • 6.4.7.4. Strategic Initiatives

List of Tables

  • TABLE 1. List of abbreviations
  • TABLE 2. Global bispecific antibodies market, by indication, 2018 - 2030 (USD Million)
  • TABLE 3. North America bispecific antibodies market, by country, 2018 - 2030 (USD Million)
  • TABLE 4. North America bispecific antibodies market, by indication, 2018 - 2030 (USD Million)
  • TABLE 5. U.S. bispecific antibodies market, by indication, 2018 - 2030 (USD Million)
  • TABLE 6. Canada bispecific antibodies market, by indication, 2018 - 2030 (USD Million)
  • TABLE 7. Europe bispecific antibodies market, by country, 2018 - 2030 (USD Million)
  • TABLE 8. Europe bispecific antibodies market, by indication, 2018 - 2030 (USD Million)
  • TABLE 9. UK bispecific antibodies market, by indication, 2018 - 2030 (USD Million)
  • TABLE 10. Germany bispecific antibodies market, by indication, 2018 - 2030 (USD Million)
  • TABLE 11. Asia Pacific bispecific antibodies market, by country, 2018 - 2030 (USD Million)
  • TABLE 12. Japan bispecific antibodies market, by indication, 2018 - 2030 (USD Million)
  • TABLE 13. China bispecific antibodies market, by indication, 2018 - 2030 (USD Million)
  • TABLE 14. Rest of World bispecific antibodies market, by country, 2018 - 2030 (USD Million)

List of Figures

  • FIG. 1 Market research process
  • FIG. 2 Information procurement
  • FIG. 3 Primary research pattern
  • FIG. 4 Market research approaches
  • FIG. 5 Value chain-based sizing & forecasting
  • FIG. 6 Market formulation & validation
  • FIG. 7 Bispecific Antibodies market segmentation
  • FIG. 8 Market snapshot, 2022
  • FIG. 9 Market trends & outlook
  • FIG. 10 Market driver relevance analysis (current & future impact)
  • FIG. 11 Market restraint relevance analysis (current & future impact)
  • FIG. 12 PESTEL analysis
  • FIG. 13 Porter's five forces analysis
  • FIG. 14 Global bispecific antibodies market: Indication movement analysis
  • FIG. 15 Global bispecific antibodies market, for cancer, 2018 - 2030 (USD Million)
  • FIG. 16 Global bispecific antibodies market, for Inflammatory & Autoimmune Disorders, 2018 - 2030 (USD Million)
  • FIG. 17 Global bispecific antibodies market, for others 2018-2030, (USD Million)
  • FIG. 18 Global bispecific antibodies market: Region movement analysis
  • FIG. 19 North America bispecific antibodies market, 2018 - 2030 (USD Million)
  • FIG. 20 U.S. bispecific antibodies market, 2018 - 2030 (USD Million)
  • FIG. 21 Canada bispecific antibodies market, 2018 - 2030 (USD Million)
  • FIG. 22 Europe bispecific antibodies market, 2018 - 2030 (USD Million)
  • FIG. 23 Germany bispecific antibodies market, 2018 - 2030 (USD Million)
  • FIG. 24 UK bispecific antibodies market, 2018 - 2030 (USD Million)
  • FIG. 25 Asia Pacific bispecific antibodies market, 2018 - 2030 (USD Million)
  • FIG. 26 Japan bispecific antibodies market, 2018 - 2030 (USD Million)
  • FIG. 27 China bispecific antibodies market, 2018 - 2030 (USD Million)
  • FIG. 28 Rest of the World bispecific antibodies market, 2018 - 2030 (USD Million)